iosbio.com
  • Home
  • Platform Technology
    • Therm-SB
  • Applications
    • Next generation biopharmaceucticals
    • Oral viral vectored proteins
    • Next generation vaccines
      • Antigen Sparing
      • Accelerated immunity
    • Cold chain enhancement
      • Thermostability
      • Alum freeze protection
  • Pipeline
    • OraPro-COVID-19
    • VZV product exemplar
    • Multi-strain Influenza vaccine
    • Novel oral protein therapeutic
    • Butyryl-cholinesterase
    • Zika virus
  • Media Centre
    • News
  • The Company
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
    • Privacy policy
    • Contact
  • Investor relations
    • Shareholder Updates
Select Page

Developing a vaccine for Coronavirus – Bloomberg

by Wayne | Mar 31, 2020 | News | 0 comments

Navid Malik, executive director of Life Sciences Division, discusses working with iosBio on a vaccine for coronavirus and how long it could be before one is on the market. He speaks on “Bloomberg Markets: European Open.” (Source: Bloomberg)

https://www.bloomberg.com/news/videos/2020-03-30/developing-a-vaccine-for-coronavirus-video

Recent posts

  • iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 12/01/2021
  • iosBio takes next step in race for a vaccine, announces BioCell as manufacturer for OraPro-COVID-19 12/06/2020
  • iosBio Biopharma earns prestigious position on WHO list of vaccine developers 11/05/2020
  • iosBio Biopharma strengthens leadership team, as Jeffrey Almond joins the board in the race to develop oral vaccine for COVID-19 07/05/2020
  • iosBio Biopharma joins race to develop COVID-19 vaccine delivering unique double immunity using self-administered capsules 30/04/2020
  • CNBC – UK biotech developing oral COVID-19 vaccine that could be delivered in the mail 07/04/2020
  • Developing a vaccine for Coronavirus – Bloomberg 31/03/2020
  • iosBio’s COVID-19 Vaccine intended to be delivered in a disruptive thermally stable oral capsule 31/03/2020
  • iosBio Biopharma announces cancer immunotherapy partnership with Oncolys BioPharma 23/05/2018
  • iosBio wins £2m Innovate UK funding for oral Zika vaccine 06/02/2018

 

iosBio Ltd
Unit 6, Sovereign Business Park
Albert Drive
Burgess Hill
RH15 9TY
United Kingdom

View Map
Telephone: +44 1444 241911
info@iosbio.com

© iosBio Ltd

 

Designed by Elegant Themes | Powered by WordPress